Arrogene In the News

Arrogene Founder Awarded $2.8 Million Federal Grant

Arrogene’s Chief Scientific Officer and co-founder, Julia Ljubimova, MD, PhD, has received a $2.8 million grant from he National Cancer Institute of the National Institutes of Health to advance her research of tumor nanoimmunology to treat cancers of the brain, breast, lung and other organs. “Our goal is to improve the body’s immune system so it can block tumors from forming,” Ljubimova said. “This new grant will allow us to continue developing a new generation of drugs that will have the ability to improve the pharmaceutical and pharmacologicalproperties of anti-cancer drugs, increase the efficacy of cancer treatment and deliver multiple types of therapeutics for combination therapy.” (more…)

Jack Kavanaugh Named Chair of Arrogene

Arrogene, Inc.,  a biotechnology company developing nano-diagnostic and therapeutic agents based on natural polymer and beta-polymalic acid, has announced that Dr. Jack Kavanaugh, a widely respected executive who has successfully led and guided multiple biotech and physical science companies, will assume the title of Chairman and Executive Chairman effective immediately.

Arrogene’s technology was developed at Cedars-Sinai Medical Center under the leadership and guidance of Julia Ljubimova, MD, PhD, director of the Nanomedicine Research Center in the Maxine Dunitz Neurosurgical Research Institute at Cedars-Sinai and founder and lead scientist at Arrogene. (more…)